内科理论与实践

内科理论与实践 >

2026 , Vol. 21 >Issue 03: 248 - 249

DOI: https://doi.org/10.16138/j.1673-6087.2026.03.08

国际证据·中国视角

奥妥珠单抗治疗原发性膜性肾病：能否成为利妥昔单抗之外的新选择？

  • 陈独群 ,
  • 程震
展开
  • 南京大学医学院附属金陵医院（东部战区总医院） 国家肾脏疾病临床医学研究中心，江苏 南京　210016
作者贡献/Authors’ Contributions陈独群负责文章初稿撰写和修改；程震负责文章的构思、修改和审定。
程 震 E-mail：chengzhen33@hotmail.com

收稿日期: 2026-06-20

  修回日期: 2026-06-21

  录用日期: 2026-07-10

  网络出版日期: 2026-08-19

基金资助

江苏省卫健委医学科研面上项目(H2023017)

版权

版权所有 © 2026 内科理论与实践编辑部
收起

Obinutuzumab for primary membranous nephropathy: can it be a new option beyond rituximab?

  • CHEN Duqun ,
  • CHENG Zhen
Expand

Received date: 2026-06-20

  Revised date: 2026-06-21

  Accepted date: 2026-07-10

  Online published: 2026-08-19

Copyright

Copyright © 2026 Journal of Internal Medicine Concepts & Practice. All rights reserved.
Fold

本文引用格式

陈独群 , 程震 . 奥妥珠单抗治疗原发性膜性肾病：能否成为利妥昔单抗之外的新选择？[J]. 内科理论与实践, 2026 , 21(03) : 248 -249 . DOI: 10.16138/j.1673-6087.2026.03.08

参考文献

[1] Fervenza FC, Hou FF, Hao CM, et al. Obinutuzumab or tacrolimus in primary membranous nephropathy[J/OL]. N Engl J Med (2026-01-05) [2026-07-08]. https://www.nejm.org/doi/10.1056/NEJMoa2602678.
[2] 陈独群, 涂远茂, 李辉, 等. 奥妥珠单抗治疗难治及高危磷脂酶A2受体相关膜性肾病的疗效观察[J]. 肾脏病与透析肾移植杂志, 2025, 34(1): 1-7.
  Chen DQ, Tu YM, Li H, et al. Obinutuzumab in treatment of high risk or refractory phospholipase A2 receptor associated membranous nephropathy[J]. Chin J Nephrol Dial Transplant, 2025, 34(1): 1-7.
[3] Hu X, Zhang M, Xu J, et al. Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy[J]. Clin J Am Soc Nephrol, 2024, 19(12): 1594-1602.
[4] Xu M, Wang Y, Wu M, et al. Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy[J]. Nephrol Dial Transplant, 2025, 40(5): 978-986.
[5] 陈独群, 王晶晶, 邱丹丹, 等. 奥妥珠单抗治疗极高危磷脂酶A2受体相关膜性肾病患者的疗效观察[J]. 肾脏病与透析肾移植杂志, 2026, 35(2): 101-106.
  Chen DQ, Wang JJ, Qiu DD, et al. Obinutuzumab in the treatment of phospholipase A2 receptor associated membranous nephropathy with very high risk: an observational study[J]. Chin J Nephrol Dial Transplant, 2026, 35(2): 101-106.
[6] Cui Z, Wei M, Li P, et al. Efficacy and safety of MIL62, a Glycoengineered Type Ⅱ Anti-CD20 antibody, in primary membranous nephropathy:a phase 3, randomized, controlled trial [C/OL]. (2025-11-08)[2026-07-08]. https://www.asn-online.org/education/kidneyweek/2025/program-abstract.aspx?controlId=4401259.
[7] Lurie A, Daneii P, Khan S, et al. Obinutuzumab versus rituximab for the treatment of primary membranous nephropathy: a systematic review and meta-analysis[J]. Life (Basel), 2026, 16(3): 434.
Options
文章导航

/

〈 〉